OPKO Health (NASDAQ:OPK) Stock Price Up 4% on Insider Buying Activity

OPKO Health, Inc. (NASDAQ:OPK)’s stock price shot up 4% on Thursday after an insider bought additional shares in the company. The company traded as high as $1.66 and last traded at $1.65. 1,068,130 shares traded hands during trading, a decline of 84% from the average session volume of 6,794,573 shares. The stock had previously closed at $1.59.

Specifically, CEO Phillip Md Et Al Frost acquired 500,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was acquired at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the completion of the transaction, the chief executive officer now directly owns 212,411,477 shares of the company’s stock, valued at $331,361,904.12. This trade represents a 0.24 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on OPK shares. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. Piper Sandler restated an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th.

OPKO Health Stock Down 1.2 %

The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The company’s fifty day moving average price is $1.53 and its 200-day moving average price is $1.47. The stock has a market cap of $1.09 billion, a P/E ratio of -8.37 and a beta of 1.62.

Institutional Trading of OPKO Health

Several institutional investors have recently added to or reduced their stakes in the company. Comerica Bank increased its stake in OPKO Health by 125.0% in the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 50,000 shares during the period. CIBC Asset Management Inc increased its stake in OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after buying an additional 8,978 shares during the period. PFG Investments LLC lifted its holdings in OPKO Health by 2.5% during the 2nd quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock valued at $1,201,000 after buying an additional 23,700 shares in the last quarter. American Century Companies Inc. purchased a new stake in OPKO Health in the 2nd quarter valued at about $112,000. Finally, Y.D. More Investments Ltd bought a new position in OPKO Health in the 2nd quarter worth about $1,840,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.